The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.

NCT06765850 · tracked via the Priya Life Science Germany tracker

Sponsor

Technische Universität Dresden

Phase

Observational

Started

2022-07-04

Last updated

2025-01-09

Condition(s) studied

Melanoma of Skin

Study summary

Prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage.

The biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Current or past history of melanoma * Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden University Hospital Exclusion Criteria: * Refusal to participate in the study * Lack of capacity to consent

Primary outcome measure(s)

Differences in metabolite concentrations — through study completion, an average of 3 years
Metabolite concentrations are measured by NMR spectroscopy and gas chromatography and compared between different subgroups.

Trial sites (1)

Facility	City	Region	Status
University Hospital Carl Gustav Carus	Dresden	Saxony	Recruiting

More Technische Universität Dresden trials in Germany

Re-irradiation of Recurrent Head and Neck Cancer Active, not recruiting

Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula Recruiting

Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn) Recruiting

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment Recruiting

A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence Active, not recruiting

Other trials for the same condition

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06765850 on ClinicalTrials.gov ↗ ← All trials in Germany